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To the Editor, 
We have read with interest the review by Abdulla et al. about the role of imaging in the 
management of progressive glioblastoma[1]. The authors have highlighted that 
pseudoprogression and radiation necrosis (late-delayed radiation effects[2]) are not 
interchangeable terms. Although some researchers have interchangeably used the terms 
radiation necrosis and pseudoprogression,[3] this practice should be avoided as there are 
differences in the clinical and radiological course of the two entities[2] and, as alluded to by 
Abdulla et al., the histopathological and molecular  phenotype of pseudoprogression has yet 
to be properly characterised.[4] Some authors also suggest that pseudoprogression is 
significantly correlated with O6 methylguanine-DNA methyltransferase (MGMT) 
promoter methylation.[5] 
Distinguishing radiation necrosis (late-delayed radiation effects[2]) and disease progression 
has been an important clinical challenge for decades which has lead to substantial imaging 
research to avoid recurrent disease being a false positive diagnosis. Since 2005 adjuvant and 
concomitant temozolomide has become the standard of care for the treatment of 
glioblastoma[6] and has lead to a large increase in the incidence of the phenomenon of 
pseudoprogression[7] which describes false positive progressive disease, typically within 6 
months of chemoradiotherapy.[8] Pseudoprogression is an early-delayed treatment effect in 
contrast to the late-delayed radiation effect,[2] and gives the neuro-oncologist a distinct set of 
management issues as the patient is receiving adjuvant temozolomide but appears to not be 
responding to treatment. Because this occurs in 20-30% of cases, this has motivated 
additional imaging research.[9] The authors have described some of these recent imaging 
studies which have been performed using perfusion, permeability and diffusion techniques. 
These do show promise in being able to differentiate pseudoprogression from progression. 
However, most of the data from the imaging studies used in Abdulla et als’ article was either 
(1) obtained in the era before adjuvant and concomitant temozolomide became the standard 
of care when early-delayed treatment effects were rare (the term ‘pseudoprogression’ had yet 
to be coined), associated with entirely different treatments and arguably had a different 
histopathological and molecular phenotype; (2) related to late-delayed radiation effects; (3) or 
was a combination of both. For example, this includes most of the data from the cited 
diffusion imaging and magnetic resonance spectroscopy studies, all the data from the single-
photon emission computed tomography imaging studies, and it is noteworthy that many of 
the [18F]fluorodeoxyglucose positron emission tomography studies are from the era when 
brain tumours were not followed up with MRI. In Abdulla et als’ review article, despite 
recognising the dangers, the authors have themselves admixed data due to radiation necrosis 
(late-delayed radiation effects), data from early-delayed treatment from before the 
temozolomide era and data from the era when temozolomide use became standard practice 
(when the term ‘pseudoprogrogression’ was adopted). 
The review article is therefore misleading to those not familiar with the evidence in this 
evolving subject. 
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